logo-loader
RNS
Allergan

Form 8.3 - Allergan plc

--(BUSINESS WIRE)--LONDON 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

2. INTERESTS ANDSHORT POSITIONS

a. Interests and short positions (following dealing) in the class ofrelevant security dealt in(Note 3)

b. Interests and short positionsin relevant securitiesof the company, other than the class dealt in (Note 3)

Ap20

(Note 4)1. DEALINGS

a. Purchases and sales

i. Exercising

b. Other dealings (including transactions in respect of new securities) (Note 4)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

 

Millennium Partners, L.P.

Source:Millennium Partners, L.P.

(Note 1)of person dealingName

Millennium International Management LP

Company dealt in

Allergan plc

(Note 2)Class of relevant security to which the dealings being disclosed relate

IE00BY9D5467

Date of dealing

30thApril 2020

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

4,439,481

 

(1.349%)

 

4,256

 

(0.001%)

 

(2) Derivatives (other than options)

-

-

(3) Options and agreements to purchase/sell

-

-

Total

4,439,481

 

(1.349%)

 

4,256

 

(0.001%)

 

 

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

 

Purchase/sale

Number of relevant securities

(Note 5)Price per unit

(USD)

Purchase

90,752

187.34

Purchase

19,615

187.34

Sale

100

187.46

Sale

100

187.47

Sale

100

187.41

Sale

100

187.49

Sale

100

187.21

Sale

100

187.45

Sale

300

187.44

Sale

200

187.14

Sale

100

187.48

Sale

100

187.22

Sale

100

187.09

Sale

41

187.18

Sale

1,584

188.41

Sale

17

188.41

Sale

549

187.84

Sale

514

188.32

Sale

5

188.30

Sale

28

187.74

Sale

417

187.65

Sale

200

188.15

Sale

214

187.36

Sale

135

187.80

Sale

58

187.67

Sale

46

187.76

Sale

318

188.35

Sale

282

187.58

Sale

53

187.82

Sale

398

187.86

Sale

11

188.13

Sale

2,168

188.01

Purchase

87,531

187.34

Sale

106

188.75

Sale

54

188.02

Sale

249

187.50

Sale

203

187.54

Sale

258

187.73

Sale

23

187.99

Sale

102

187.21

Sale

194

187.91

Sale

142

188.00

Sale

137

188.33

Sale

263

188.41

Purchase

263

187.34

Purchase

17

188.41

Sale

94

187.98

Sale

200

188.20

Sale

7

187.64

Sale

110

188.32

Purchase

70

188.79

Sale

6

187.74

Sale

535

187.65

Sale

100

188.15

Sale

100

187.76

Sale

104

188.11

Sale

3

187.58

Sale

27

187.82

Sale

2

187.86

Purchase

39,646

187.34

Sale

110,367

187.34

Sale

100

188.02

Sale

104

188.28

Sale

1

187.90

Sale

2

187.68

Purchase

711

187.46

Sale

202

187.46

Sale

2

187.47

Sale

100

187.95

Sale

1

187.94

Sale

2

188.38

Purchase

70

188.22

Sale

3

188.22

Sale

1,034

187.99

Sale

4

187.89

Sale

1

188.37

Sale

2

187.87

Sale

35

188.08

Sale

1

187.72

Sale

25

187.62

Sale

1

187.92

Sale

1

187.61

Sale

2

188.17

Sale

100

187.63

Sale

1

188.00

Sale

21

188.07

Sale

3

188.04

Sale

2

187.66

Sale

62

187.51

Sale

2

187.60

Sale

1

187.59

Sale

4

187.70

Sale

1

187.56

Sale

1

187.57

Sale

462

187.39

Sale

4

187.75

Sale

100

188.27

Sale

39,646

187.34

Product name,

e.g. call option

Number of securities

(Note 5)Exercise price per unit

 

 

 

Nature of transaction

(Note 8)

Details

Price per unit

(Note 5)(if applicable)

 

 

 

 

 

 

 

(Note 9)Is a Supplemental Form 8 attached?NO

Date of disclosure

1stMay 2020

Contact name

Milos Naumovic

Telephone number

+44 203 650 8203

If a connected EFM, name of offeree/offeror with which connected

 

(Note 10)If a connected EFM, state nature of connection

 

 

NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read